Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Humanin

HN, S14G-Humanin

Quick Stats
Studies 491
Trials 100
Score 3
2022 pubmed 5 citations

Humanin Ameliorates Late-onset Hypogonadism in Aged Male Rats.

El Kattawy. Hany A HA; Abozaid. Eman R ER; Abdullah. Doaa M DM

Key Findings

  • Humanin raised serum testosterone in aged hypogonadal rats
  • Improved sperm count, motility, and morphology after humanin treatment
  • Reduced oxidative damage markers and apoptosis while increasing antioxidant defenses via Nrf2-ARE pathway

Practical Outcomes

  • Humanin shows promise as a natural peptide that could counter age‑related testosterone decline and testicular damage, but the evidence is limited to rats. Biohackers might watch for human trials, but any self‑experiment should proceed cautiously, considering dosage, delivery method, and safety data are not yet established.

Summary

In older male rats with low testosterone, giving the mitochondrial peptide humanin boosted testosterone levels, improved sperm quality, and reduced oxidative stress and cell death in the testes, likely by activating antioxidant pathways.

Abstract

The potential to reproduce declines with age. Late-onset hypogonadism is characterized by reduced serum testosterone. Humanin is a mitochondrial-derived signaling peptide encoded by short open reading frames within the mitochondrial genome. It may protect against some age-related diseases such as atherosclerosis by its cytoprotective effects. The study aimed to investigate the potential anti-aging effects of humanin on the testicular architecture, oxidative stress, some apoptotic and inflammatory markers in the hypogonadal aged male rats. Forty male albino rats were divided into 4 groups: normal adult controls, aged vehicle- treated group, aged testosterone-treated group, and aged humanin-treated group. Twenty-month- old male rats with declined serum testosterone were selected to be the animal models of lateonset hypogonadism. Testicular weights, serum testosterone, and some sperm parameters were measured. Testicular tissue IL-6 and TNF-α, superoxide dismutase activity, glutathione peroxidase, and malondialdehyde were assessed. The activity of caspase-3, BCL2, PCNA, and the nuclear factor erythroid 2-related factor 2-antioxidant response element pathway were evaluated. Testes were subjected to histopathological and immunohistochemical examination. Statistical analysis was executed using. One Way Analysis of variance (ANOVA) followed by Post hoc (LSD) test to compare means among all studied groups. Humanin treatment significantly improved serum testosterone, sperm characteristics, and antioxidant defenses. It decreased active caspase-3, pro-apoptotic BAX expression, and increased antiapoptotic BCL2 and proliferating cell nuclear antigen (PCNA) possibly via activating the (Nrf2- ARE) pathway. Humanin might be a promising therapeutic modality in late-onset hypogonadism as it ameliorated some age-related testicular and hormonal adverse effects.

Study Information

Provider

pubmed

Year

2022

Date

2022-01-27T00:00:00.000Z

DOI

10.2174/1874467215666220127115602

Citations

5